 TORONTO, ON ACCESSWIRE April 20, 2020 Edesa Biotech, Inc. EDSA, a clinical-stage biopharmaceutical company, today announced a strategic agreement with Light Chain Bioscience a brand of NovImmune SA, a leading Swiss pharmaceutical development company, for an exclusive worldwide license to develop and commercialize two Phase 2-ready biologic drug candidates for all therapeutic, prophylactic and diagnostic applications. Edesa plans to pursue the development of these signaling molecules as potential treatments for acute respiratory distress syndrome and lung injury resulting from viral respiratory infections, such as the coronavirus that causes COVID-19, and other disorders. 